Kymab milestone payment

Schroders Capital Global Innovation
05 February 2024
 

 

 

Schroders Capital Global Innovation Trust Plc

Kymab milestone payment

 

Schroders Capital Global Innovation Trust plc (the "Company") is pleased to announce that it has received a $5.8 million (c. £4.6 million) distribution related to the first milestone of the Kymab sale to Sanofi.

In April 2021, the Company announced the completion of the sale of its shares in Kymab to Sanofi, generating initial proceeds of $87 million (£65 million). At that time, the Company explained there was the potential for additional contingent payments of up to $27 million (£20 million) subject to the achievement of various development and regulatory milestones. This announced payment reflects the first milestone event, with the potential for $21 million of further contingent payments in the future.

This uplift of c. £4.6 million will be reflected in the Company's unaudited NAV per share, dated Friday 2 February 2024, published later today.

 

Enquiries:

Schroder Investment Management Limited

Shilla Pindoria (Company Secretary)

0207 658 6000

Augustine Chipungu (Press)

0207 658 2106

John Spedding (Head of Investment Trusts)

0207 658 3206

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings